AUTL Autolus Therapeutics plc: institutional ownership and insider trading
87 funds reported holding $218M of Autolus Therapeutics plc in their latest 13F filings; in Q2 2026 funds net sold $3.63M, with 8 new positions and 10 funds selling out; over the last 12 months insiders bought $0 and sold $15.7K on the open market.
Famous investors holding AUTL
- Renaissance Technologies (Renaissance Technologies): $3.18M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $1.96M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $1.29M, 0.0% of the portfolio
Largest institutional holders of AUTL
- MAK CAPITAL ONE LLC — $53.8M
- Blackstone Inc. (BX) — $32.8M
- Syncona Portfolio Ltd — $26.6M
- ARMISTICE CAPITAL, LLC — $24.0M
- TFG Asset Management GP Ltd — $15.2M
- SCHRODER INVESTMENT MANAGEMENT GROUP — $12.9M
- Frazier Life Sciences Management, L.P. — $7.12M
- AXA Investment Managers S.A. — $5.48M
- BNP Paribas Asset Management Holding S.A. — $5.38M
- Laurion Capital Management LP — $5.31M
Recent AUTL insider trades
- Sep 2, 2026: Piccina Cintia sold 6,713 shares ($15.7K)
5%+ owners
- MAK Capital Fund LP: 12.6% (Schedule 13G/A, filed May 15, 2026)
- Armistice Capital, LLC: 5.6% (Schedule 13G/A, filed Aug 14, 2026)
- Renata Kellnerova: 5.6% (Schedule 13D/A, filed Aug 28, 2026)